Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

CPWY , CMPS
Sort by: Date|Relevance

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

A psilocybin mushroom, also known as a magic mushroom, offers infinite medical and scientific potential…from cognitive flexibility to potentially addressing clinical depression and eating disorders. There’s a lot we still don’t kn...
Dave Jackson | September 18, 2020 |

Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan

aTyr Pharma's shares traded 45% higher today after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan. This morning, biotherapeutics company aTyr Pharma I...
Streetwise Reports | January 7, 2020 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences

Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. Clin...
Streetwise Reports | June 12, 2020 |

US Memorial Day Weekend Market Analysis

The US Memorial Day weekend is set up to become a very interesting time for investors. The EU voting is complete and the change in EU leadership may move the markets a bit. China appears to be playing a waiting game – attempting to hold the US/Trump at bay until after the 2020...
Chris Vermeulen | June 10, 2019 |

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation

Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. This morning, shares of clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ) , which is focused on pioneering treatments for autoimmune and...
Streetwise Reports | February 19, 2020 |

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. Clinical-stage...
Streetwise Reports | October 15, 2019 |

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report

Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. Structural heart disease and critical care monitor...
Streetwise Reports | July 25, 2019 |

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. Developer of precision immunodiagnostic agents and immunotherape...
Streetwise Reports | October 30, 2019 |
1 2 3